May 29, 2025
Francisco Salva, President and CEO of Azitra, Inc., is leveraging the microbial bacteria that comprise the skin microbiome and exploring novel methods to deliver precision medicines to the skin. Azitra has genetically engineered specific strains of these microbes to produce proteins that are missing in patients with...
May 29, 2025
Francisco Salva, President and CEO of Azitra, Inc., is leveraging the microbial bacteria that comprise the skin microbiome and exploring novel methods to deliver precision medicines to the skin. Azitra has genetically engineered specific strains of these microbes to produce proteins that are missing in patients with...
Feb 27, 2023
Neal Koller is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected...
Feb 27, 2023
Neal Koller is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected...
Feb 13, 2023
Dr. Joslyn Kirby is the President of the HS Foundation, which focuses on improving the lives of those who suffer from Hidradenitis Suppurativa, a skin condition caused by an overactive immune system. Generally people with this condition are misdiagnosed with skin infections and treated with ineffective antibiotics. As...